Publications by authors named "Aizhong Qu"

2 Publications

  • Page 1 of 1

Matrine ameliorates the inflammatory response and lipid metabolism in vascular smooth muscle cells through the NF-κB pathway.

Exp Ther Med 2021 Nov 16;22(5):1309. Epub 2021 Sep 16.

Department of Emergency Medicine, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China.

Atherosclerosis is a chronic inflammatory disease associated with inflammatory responses and the uncontrolled proliferation and excessive apoptosis of vascular smooth muscle cells. However, the effects of matrine on the inflammatory response, abnormal lipid metabolism and cell proliferation and apoptosis marker proteins in human aortic vascular smooth muscle cells (HAVSMCs) have not been elucidated. Therefore, the present study aimed to investigate the effect of matrine on an model of atherosclerosis using HAVSMCs. The HAVSMCs were divided into normal, model and matrine groups. The model group was treated with oxidized low-density lipoprotein (oxLDL), the matrine group was treated with oxLDL and matrine and the normal group was treated with physiological saline. Total cholesterol (TC), free cholesterol (FC) and cholesterol ester (CE) levels were measured in the cell supernatant. In addition, the relative mRNA levels of inflammatory factors were quantified using reverse transcription-quantitative PCR, and the cell proliferation and apoptosis rates were evaluated using Cell Counting Kit-8 and flow cytometry assays, respectively. The expression levels of proteins associated with proliferation and apoptosis were also determined using western blotting. The levels of TC, FC and CE and the mRNA levels of IL-1β, IL-6, and TNF-α in the matrine group were lower than those in the model group, but higher than those in the normal group. After 48 and 96 h of treatment, the cell proliferation and apoptotic rates were lower in the matrine group compared with the model group. The relative expression levels of Ki-67, proliferating cell nuclear antigen and Bax were decreased, while that of Bcl-2 was increased in the matrine group compared with the model group. In addition, the relative protein expression of nuclear factor κB (NF-κB) in the matrine group was lower than that in the model group, but higher than that in the normal group. In summary, matrine inhibited activation of the NF-κB pathway and reduced cell proliferation and apoptosis in the oxLDL-induced atherosclerosis model, and exhibited anti-inflammatory effects. These results suggest that matrine attenuated abnormal biological reactions in HAVSMCs through the NF-κB pathway.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2021.10744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461614PMC
November 2021

Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.

Br J Radiol 2021 Aug 14;94(1124):20201088. Epub 2021 Jul 14.

Department of Oncology, Shandong Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Objective: The aim of this study was to compare the clinical efficacy of neoadjuvant chemoradiotherapy (NACRT) combined with postoperative adjuvant XELOX (Oxaliplatin +Capecitabine) chemotherapy and postoperative adjuvant chemotherapy (ACT) with XELOX for local advanced gastric cancer (LAGC).

Methods: In this prospectively randomized trial, we investigated the effect of NACRT combined with postoperative ACT for LAGC. 60 patients were randomly divided into NACRT group and ACT group, with 30 patients in each group. Patients in NACRT group were given three-dimensional conformal radiotherapy (45 Gy/1.8 Gy/f) accompanied by synchronous XELOX of two cycles, followed by surgery, and then postoperative adjuvant XELOX chemotherapy of four cycles was performed. Patients in ACT group received surgery in advance, and then XELOX chemotherapy of six cycles was given.

Results: The objective response rate of NACRT was 76.7%. The overall incidence of postoperative complications in NACRT group was not significantly different from that in ACT group (23.1% 30.0%, = 0.560). The 1 year, 2 years, and 3 years progression-free survival (PFS)and overall survival (OS) in NACRT and ACT groups were 80.0% 56.7%, 73.3% 46.7%, 60.0% 33.3%, and 86.7% 80.0%, 76.7% 66.7%, 63.3% 50.0%, respectively. Patients in NACRT group showed a significantly higher R0 resection rate (84.6% 56.7%, = 0.029),lower loco-regional recurrence rate (36.7% 11.5%, = 0.039), longer PFS ( = 0.019) and freedom from locoregional progression(FFLP) ( = 0.004) than patients in ACT group, while there was no difference in OS ( = 0.215) and in toxicity incidence ( > 0.05).

Conclusions: NACRT combined with postoperative adjuvant XELOX chemotherapy can improve R0 resection rate, reduce loco-regional recurrence, prolong PFS and FFLP without increasing the incidence of postoperative complications in patients with LAGC.

Advances In Knowledge: Compared with postoperative adjuvant chemotherapy, locally advanced gastric cancer patients may benefit from neoadjuvant chemoradiotherapy, and toxicity associated with chemoradiotherapy was tolerant and manageable.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20201088DOI Listing
August 2021
-->